Who We Are

Apexray Biotech is a boutique international pharmaceutical consulting and business development firm focused on cross-border dealmaking. We specialize in API, Finished Dosage Forms, CDMO/CMO partnerships, and both licensing-out and licensing-in opportunities for generic, 505(b)(2) and clinical-stage new drug.

We work with API manufacturers, finished dosage form pharmaceutical companies, CDMOs/CMOs and biotech firms across Asia, Japan, Europe and North America, providing practical, hands-on BD support rather than generic advisory slides. Our role is to act as your external BD arm for complex international opportunities – from identifying the right partners to preparing, negotiating and closing commercially meaningful deals.

Our Mission

Our mission at Apexray is to turn complex cross-border opportunities into sustainable international growth for our clients – expanding their market footprint and translating strong APIs, finished products, and new drug pipelines into successful licensing-out /in deals, real revenues, and long-term partnerships across Europe, North America, and Asia.

Our Services

Practical solutions tailored to your consulting needs.

API Sourcing & Second-Source Strategy

Whether you are sourcing a new API or de-risking an existing product, Apexray helps you identify and qualify reliable manufacturers, benchmark pricing and supply terms, and—where appropriate—build second- and multi-source API strategies across Taiwan, India, China, Europe, and other key hubs

Cross-Border CDMO & Manufacturing Partnerships

When your products are headed for the US, Europe, Japan, or other highly regulated markets, Apexray helps you identify CDMOs whose facilities, equipment, and quality systems truly match your manufacturing processes for the relevant dosage forms and the intended regulatory pathway in those markets – and supports you from requirements definition through partner selection and MSA/SOW negotiation.

Whether you’re out-licensing or in-licensing generics, 505(b)(2) products, or clinical-stage candidates, Apexray helps you target the right partners and markets, quantify asset value, and structure licensing and co-development deals – with data-driven economics and end-to-end BD support from outreach through due diligence.

Licensing & Co-Development Deals 【Generic, 505(b)(2), clinical-stage new drug】

News Hub

CPhI Frankfurt 2025

APEXRAY will be attending CPhI Frankfurt 2025 to discuss API sourcing, and CDMO partnerships, and co-development opportunities.

BioEurope Vienna 2025

APEXRAY will be at BioEurope Vienna 2025, meeting with pharma and biotech companies to explore licensing, co-development, and broader BD partnership opportunities across generics, 505(b)(2) and clinical-stage assets.